Literature DB >> 25499450

Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

Kieron Dunleavy1, Wyndham H Wilson1.   

Abstract

Primary mediastinal B-cell lymphoma (PMBL) is a subtype of diffuse large B-cell lymphoma (DLBCL) that is putatively derived from a thymic B cell. Accounting for up to 10% of cases of DLBCL, this subtype predominantly affects women in the third and fourth decades of life. Its clinical and molecular characteristics are distinct from other subtypes of DLBCL and, in fact, closely resemble those of nodular sclerosing Hodgkin lymphoma (NSHL). Recently, mediastinal lymphomas with features intermediate between PMBL and NSHL, called mediastinal gray-zone lymphomas, have been described. The optimal management of PMBL is controversial, and most standard approaches include a combination of immunochemotherapy and mediastinal radiation. Recently, the recognition that mediastinal radiation is associated with significant long-term toxicities has led to the development of novel approaches for PMBL that have shown excellent efficacy and challenge the need for routine mediastinal radiation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25499450      PMCID: PMC4281829          DOI: 10.1182/blood-2014-05-575092

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.

Authors:  P L Zinzani; M Martelli; M Magagnoli; E Pescarmona; L Scaramucci; F Palombi; M Bendandi; M P Martelli; S Ascani; G F Orcioni; S A Pileri; F Mandelli; S Tura
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

2.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

Authors:  R Angelo de Claro; Karen McGinn; Virginia Kwitkowski; Julie Bullock; Aakanksha Khandelwal; Bahru Habtemariam; Yanli Ouyang; Haleh Saber; Kyung Lee; Kallappa Koti; Mark Rothmann; Marjorie Shapiro; Francisco Borrego; Kathleen Clouse; Xiao Hong Chen; Janice Brown; Lara Akinsanya; Robert Kane; Edvardas Kaminskas; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-09-07       Impact factor: 12.531

5.  [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Authors:  Maurizio Martelli; Luca Ceriani; Emanuele Zucca; Pier Luigi Zinzani; Andrés J M Ferreri; Umberto Vitolo; Caterina Stelitano; Ercole Brusamolino; Maria Giuseppina Cabras; Luigi Rigacci; Monica Balzarotti; Flavia Salvi; Silvia Montoto; Armando Lopez-Guillermo; Erica Finolezzi; Stefano A Pileri; Andrew Davies; Franco Cavalli; Luca Giovanella; Peter W M Johnson
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

6.  Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Franziska C Eberle; Jaime Rodriguez-Canales; Lai Wei; Jeffrey C Hanson; J Keith Killian; Hong-Wei Sun; Lisa G Adams; Stephen M Hewitt; Wyndham H Wilson; Stefania Pittaluga; Paul S Meltzer; Louis M Staudt; Michael R Emmert-Buck; Elaine S Jaffe
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

7.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

8.  Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.

Authors:  Jacob D Soumerai; Matthew D Hellmann; Yang Feng; Aliyah R Sohani; Christiana E Toomey; Jeffrey A Barnes; Ronald W Takvorian; Donna Neuberg; Ephraim P Hochberg; Jeremy S Abramson
Journal:  Leuk Lymphoma       Date:  2013-07-29

9.  Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Authors:  Yansheng Hao; Bjoern Chapuy; Stefano Monti; Heather H Sun; Scott J Rodig; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  26 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  Taking gray zone lymphomas out of the shadows.

Authors:  Elías Campo; Elaine S Jaffe
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Authors:  Monika Pilichowska; Stefania Pittaluga; Judith A Ferry; Jessica Hemminger; Hong Chang; Jennifer A Kanakry; Laurie H Sehn; Tatyana Feldman; Jeremy S Abramson; Athena Kritharis; Francisco J Hernandez-Ilizaliturri; Izidore S Lossos; Oliver W Press; Timothy S Fenske; Jonathan W Friedberg; Julie M Vose; Kristie A Blum; Deepa Jagadeesh; Bruce Woda; Gaurav K Gupta; Randy D Gascoyne; Elaine S Jaffe; Andrew M Evens
Journal:  Blood Adv       Date:  2017-12-11

5.  Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Authors:  Pier Luigi Zinzani; Armando Santoro; Giuseppe Gritti; Pauline Brice; Paul M Barr; John Kuruvilla; David Cunningham; Justin Kline; Nathalie A Johnson; Neha Mehta-Shah; Thomas Manley; Stephen Francis; Manish Sharma; Alison J Moskowitz
Journal:  J Clin Oncol       Date:  2019-08-09       Impact factor: 44.544

Review 6.  PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

Authors:  Aaron Goodman; Sandip P Patel; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-11-02       Impact factor: 66.675

7.  Composite Lymphoma: Opposite Ends of Spectrum Meet.

Authors:  Uqba Khan; Tarik Hadid; Warda Ibrar; Dahlia Sano; Ayad Al-Katib
Journal:  J Clin Med Res       Date:  2017-01-25

8.  Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association.

Authors:  Clémentine Sarkozy; Thierry Molina; Hervé Ghesquières; Anne-Sophie Michallet; Jehan Dupuis; Diane Damotte; Franck Morsschauser; Marie Parrens; Laurent Martin; Peggy Dartigues; Aspasia Stamatoullas; Pierre Hirsch; Bettina Fabiani; Krimo Bouabdallah; Maria Gomes da Silva; Marie Maerevoet; Camille Laurent; Bertrand Coiffier; Gilles Salles; Alexandra Traverse-Glehen
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 9.  Antibody Therapies for Large B-Cell Lymphoma.

Authors:  Mattia Novo; Elisa Santambrogio; Pio Manlio Mirko Frascione; Delia Rota-Scalabrini; Umberto Vitolo
Journal:  Biologics       Date:  2021-05-18

10.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Authors:  Anna Dalla Pietà; Elisa Cappuzzello; Roberta Sommaggio; Antonio Rosato; Pierangela Palmerini; Annavera Ventura; Andrea Visentin; Giuseppe Astori; Katia Chieregato; Valentina Mozzo; Omar Perbellini; Maria Chiara Tisi; Livio Trentin; Carlo Visco; Marco Ruggeri
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.